

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet 1 of 39

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2,711,411	06-21-1955	Holbert, <i>et al.</i>	All
	U2	US-4,198,507	04-15-1980	Barry, <i>et al.</i>	All
	U3	US-4,368,197	01-11-1983	Shefter, <i>et al.</i>	All
	U4	US-4,994,604	02-19-1991	Tung, <i>et al.</i>	All
	U5	US-5,177,262	01-15-1993	Taylor, <i>et al.</i>	All
	U6	US-5,332,834	07-26-1994	Bhattacharya, <i>et al.</i>	All
	U7	US-5,338,644	08-16-1994	Taylor, <i>et al.</i>	All
	U8	US-5,380,867	01-10-1995	Bhattacharya, <i>et al.</i>	All
	U9	US-5,412,094	05-02-1995	Amos, <i>et al.</i>	All
	U10	US-5,523,090	06-04-1996	Znaiden, <i>et al.</i>	All
	U11	US-5,614,342	03-25-1997	Molaire, <i>et al.</i>	All
	U12	US-5,998,413	12-07-1999	Heeres, <i>et al.</i>	All
	U13	US-6,001,996	12-14-1999	Amos, <i>et al.</i>	All
	U14	US-6,268,385	07-31-2001	Whittle, <i>et al.</i>	All
	U15	US-6,570,036	05-27-2003	Reuter	All
	U16	US-2003/0162226	08-28-2003	Cima, <i>et al.</i>	All
	U17	US-2003/0166581	09-04-2003	Almarsson, <i>et al.</i>	All
	U18	US-2003/0224006	12-04-2003	Zaworotko, <i>et al.</i>	All
	U19	US-2004/0019211	01-29-2004	Remenar, <i>et al.</i>	All
	U20	US-2004/0106052	06-03-2004	Molaire	All
	U21	US-2004/0106053	06-03-2004	Molaire, <i>et al.</i>	All
	U22	US-2004/0106055	06-03-2004	Molaire, <i>et al.</i>	All
	U23	US-2004/0171062	09-02-2004	Hirth, <i>et al.</i>	All

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

J:\TPI2900C3XC2\PTO\DS-form-suppl.doc\DNB/jb

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet	2	of	39
-------	---	----	----

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U24	US-2004/0176335	09-09-2004	Childs	All
	U25	US-2004/0053853	03-18-2004	Almarsson, <i>et al.</i>	All
	U26	US-2005/0070551	03-31-2005	Remenar, <i>et al.</i>	All
	U27	US-2005/0070551 A1	03-31-2005	Remenar, <i>et al.</i>	All
	U28	US-2005/0169982	08-04-2005	Almarsson, <i>et al.</i>	All
	U29	US-2005/0181041	08-18-2005	Goldman	All
	U30	US-2005/0252649	11-17-2005	Chiu, <i>et al.</i>	All
	U31	US-2005/0256127	11-17-2005	Ku, <i>et al.</i>	All
	U32	US-3,536,809	04-09-1991	Schaller <i>et al.</i>	All
	U33	US-3,598,123	08-10-1971	Zaffaroni	All
	U34	US-3,845,770	11-05-1974	Theeuwes <i>et al.</i>	All
	U35	US-3,916,899	11-04-1975	Theeuwes <i>et al.</i>	All
	U36	US-4,267,179	05-12-1981	Heeres <i>et al.</i>	All
	U37	US-4,764,604	08-16-1988	Muller	All
	U38	US-4,916,134	04-10-1990	Heeres <i>et al.</i>	All
	U39	US-5,006,513	04-09-1991	Hector <i>et al.</i>	All
	U40	US-5,059,595	10-22-1991	Le Grazie	All
	U41	US-5,073,543	12-17-1991	Marshall <i>et al.</i>	All
	U42	US-5,120,548	06-09-1992	McClelland <i>et al.</i>	All
	U43	US-6,559,293	05-06-2003	Almarsson, <i>et al.</i>	All
	U44	US-6,699,840	03-02-2004	Almarsson, <i>et al.</i>	All

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet	3	of	39
-------	---	----	----

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U45	US-5,354,556	10-11-1994	Sparks <i>et al.</i>	All
	U46	US-5,414,997	05-16-1995	Tailer	All
	U47	US-5,474,997	12-12-1995	Gray <i>et al.</i>	All
	U48	US-5,591,767	01-07-1997	Mohr <i>et al.</i>	All
	U49	US-5,633,015	05-27-1997	Gillis <i>et al.</i>	All
	U50	US-5,639,476	06-17-1997	Oshlack <i>et al.</i>	All
	U51	US-5,661,151	08-26-1997	Saksena <i>et al.</i>	All
	U52	US-5,674,533	10-07-1997	Santus <i>et al.</i>	All
	U53	US-5,707,975	01-13-1998	Francois <i>et al.</i>	All
	U54	US-5,733,566	03-31-1998	Lewis	All
	U55	US-2003/0096014	05-22-2003	Sherman	All
	U56	US-4,513,006	04-23-1985	Maryanoff <i>et al.</i>	All
	U57	US-6,191,117	02-20-2001	Kozachuk	All
	U58	US-6,201,010	03-13-2001	Cottrell	All
	U59	US-5,753,693	05-19-1998	Shank	All
	U60	US-5,998,380	12-07-1999	Ehrenberg <i>et al.</i>	All
	U61	US-6,319,903	11-20-2001	Carrazana <i>et al.</i>	All
	U62	US-5,935,933	08-10-1999	Shank <i>et al.</i>	All
	U63	US-5,760,007	06-02-1998	Shank <i>et al.</i>	All
	U64	US-5,952,187	09-14-1999	Stenglein <i>et al.</i>	All
	U65	US-5,242,942	09-07-1993	Costanzo <i>et al.</i>	All
	U66	US-5,384,327	01-24-1995	Costanzo <i>et al.</i>	All
	U67	US-6,071,537	06-06-2000	Shank	All

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U68	US- 7,078,526	07-18-2006	Remenar <i>et al.</i>	All
	U69	US-2002/0037925	03-28-2002	Dewey <i>et al.</i>	All
	U70	US-2002/0042446	04-11-2002	Dewey <i>et al.</i>	All
	U71	US-2003/0069190	04-10-2003	Abdel-Magid <i>et al.</i>	All
	U72	US-2003/0072802	04-17-2003	Cutler	All
	U73	US-4,008,321	02-15-1977	Kamishita <i>et al.</i>	All
	U74	US-5,466,823	11-14-1995	Talley <i>et al.</i>	All
	U75	US-6,294,192	9-25-2001	Patel <i>et al.</i>	All
	U76	US-6,488,962	12-03-2002	Berner <i>et al.</i>	All
	U77	US-6,503,884	01-07-2003	Ehrenberg <i>et al.</i>	All
	U78	US-3,028,420	04-03-1962	Petrow <i>et al.</i>	All
	U79	US-5,521,207	05-28-1996	Graneto	All
	U80	US-2,665,277	01-05-1954	Homeyer <i>et al.</i>	All
	U81	US-4,927,855	05-22-1990	Lafon	All
	U82	US-5,023,092	06-11-1991	DuRoss	All
	U83	US-5,273,760	12-28-1993	Oshlack <i>et al.</i>	All
	U84	US-5,286,493	02-15-1994	Oshlack <i>et al.</i>	All
	U85	US-5,324,351	06-28-1994	Oshlack <i>et al.</i>	All
	U86	US-5,356,467	10-18-1994	Oshlack <i>et al.</i>	All
	U87	US-5,366,738	11-22-1994	Rork <i>et al.</i>	All
	U88	US-5,472,712	12-05-1995	Oshlack <i>et al.</i>	All
	U89	US-5,510,496	04-23-1996	Talley <i>et al.</i>	All

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet	5	of	39
-------	---	----	----

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U90	US-5,521,207	05-28-1996	Graneto	All
	U91	US-5,563,165	10-08-1996	Talley <i>et al.</i>	All
	U92	US-5,631,250	05-20-1997	Bunnell <i>et al.</i>	All
	U93	US-5,633,272	05-27-1997	Talley <i>et al.</i>	All
	U94	US-5,703,232	12-30-1997	Bunnell <i>et al.</i>	All
	U95	US-5,753,688	05-19-1998	Talley <i>et al.</i>	All
	U96	US-5,932,598	08-03-1999	Talley <i>et al.</i>	All
	U97	US-5,972,986	10-26-1999	Seibert <i>et al.</i>	All
	U98	US-5,985,902	11-16-1999	Talley <i>et al.</i>	All
	U99	US-6,132,420	10-17-2000	Dionne <i>et al.</i>	All
	U100	US-6,156,781	12-05-2000	Talley <i>et al.</i>	All
	U101	US-6,245,357	06-12-2001	Edgren <i>et al.</i>	All
	U102	US-6,270,787	08-07-2001	Ayer	All
	U103	US-6,283,953	09-04-2001	Ayer <i>et al.</i>	All
	U104	US-6,287,295	09-11-2001	Chen <i>et al.</i>	All
	U105	US-6,323,266	11-27-2001	Phillips	All
	U106	US-6,333,050	12-25-2001	Wong <i>et al.</i>	All
	U107	US-6,342,249	01-29-2002	Wong <i>et al.</i>	All
	U108	US-6,348,458	02-19-2002	Hamied <i>et al.</i>	All
	U109	US-6,365,185	04-02-2002	Ritschel <i>et al.</i>	All
	U110	US-6,368,626	04-09-2002	Bhatt <i>et al.</i>	All
	U111	US-6,375,978	04-23-2002	Kleiner <i>et al.</i>	All

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U112	US-6,384,034	05-07-2002	Simitchieva <i>et al.</i>	All
	U113	US-6,403,640	06-11-2002	Stoner <i>et al.</i>	All
	U114	US-6,413,965	07-02-2002	Mylari	All
	U115	US-6,579,895	06-17-2003	Karim <i>et al.</i>	All
	U116	US-6,613,790	09-02-2003	Carter	All
	U117	US-7,172,769	02-06-2007	Kararli <i>et al.</i>	All
	U118	US-7,205,413	04-17-2007	Morissette <i>et al.</i>	All
	U119	US-7,446,107	11-04-2008	Remenar <i>et al.</i>	All
	U120	US-7,452,555	11-18-2008	Childs	All
	U121	US-7,459,449	12-02-2008	Keltjens	All
	U122	US-2002/0013357	01-31-2002	Nadkarni <i>et al.</i>	All
	U123	US-2002/0006951	01-17-2002	Hageman <i>et al.</i>	All
	U124	US-2002/0015735	02-07-2002	Hedden <i>et al.</i>	All
	U125	US-2002/0034542	03-21-2002	Thombre <i>et al.</i>	All
	U126	US-2002/0071857	06-13-2002	Kararli <i>et al.</i>	All
	U127	US-2002/0119193	08-29-2002	Le <i>et al.</i>	All
	U128	US-2002/0107250	08-08-2002	Hariharan <i>et al.</i>	All
	U129	US-2004/0029946	02-12-2004	Arora <i>et al.</i>	All
	U130	US-2004/0154890	08-12-2004	Liu	All
	U131	US-2004/0242640	12-02-2004	Desai <i>et al.</i>	All
	U132	US-2007/0015841	01-18-2007	Tawa <i>et al.</i>	All

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U133	US-2007/0293674	12-20-2007	Scoppettuolo <i>et al.</i>	All
	U134	US-7,132,570	11-07-2006	Neckebroock <i>et al.</i>	All
	U135	US-2006/0223794	10-05-2006	Hickey <i>et al.</i>	All
	U136	US-2007/0021510	01-25-2007	Hickey <i>et al.</i>	All
	U137	US-2007/0059356	03-15-2007	Almarsson <i>et al.</i>	All
	U138	US-7,132,579	11-07-2006	Neckebroock <i>et al.</i>	All

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1	WO 01/45706	06-28-2001	Pharmacia Corporation	All	
	F2	WO 2002/102376	12-27-2002	Pharmacia Corporation	All	
	F3	WO 2002/10125	02-07-2002	Teva Pharmaceutical Industries Ltd.	All	
	F4	WO 2002/056915	07-25-2002	Cephalon, Inc.	All	
	F5	WO 2005/053612	06-16-2005	Shire Laboratories, Inc.	All	
	F6	WO 96/33193	10-24-1996	Janssen Pharmaceutica N.V.	All	
	F7	JP 54-095589	07-28-1979	Sumitomo Chemical Co. Ltd.	All	
	F8	FR 2,849,029	06-25-2004	Laboratoire L. Lafon	All	
	F9	EP 413528 B1	11-15-1995	Yu, R. <i>et al.</i>	All	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

JATPI2900C3XC2\PTOIDS-form-suppl.doc/DNB/jb

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/747,742
				Filing Date	December 29, 2003
				First Named Inventor	Mark Tawa
				Art Unit	1623
				Examiner Name	Jonathan S. Lau
Sheet	8	of	39	Attorney Docket Number	TPI.2900C3XC2

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)					
	F10	EP 0283992 B1		09-16-1992	Janssen Pharma	All	
	F11	EP 0310122 B1		04-05-1989	Kaken Pharma	All	
	F12	EP 1364649 A1		11-26-2003	Cilag AG	All	
	F13	FR 769,586		06-11-1934	Chemische Fabrik von Heyden	All	
	F14	IT 01303251		11-06-2000	Industriale Chimica, S.R.L.	All	
	F15	JP 54-16494		02-07-1979	Yamanouchi Pharmaceutical Co., Ltd.	All	
	F16	WO 00/50020 A2		08-31-2000	University of Cincinnati	All	
	F17	WO 2000/53283 A1		09-14-2000	Reuter Chemische Apparatebau KG	All	
	F18	WO 2001/13904 A2		03-01-2001	Ortho-McNeil Pharmaceutical, Inc.	All	
	F19	WO 2001/97853 A1		12-27-2001	Biochemie Gesellschaft MBH	All	
	F20	WO 2002/062318 A2		08-15-2002	DSM N.V.	All	
	F21	WO 94/16733 A1		08-04-1994	Chiesi Farmaceutici S.P.A.	All	
	F22	WO 96/07331 A1		03-14-1996	Xyrofin Oy	All	
	F23	WO 98/57967 A1		12-23-1998	Dong-A Pharmaceutical Co., Ltd.	All	
	F24	WO 2003/101392 A2		12-11-2003	Transform Pharmaceuticals, Inc.	All	

Examiner Signature	/Jonathan Lau/	Date Considered	04/13/2010
-----------------------	----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/747,742
				Filing Date	December 29, 2003
				First Named Inventor	Mark Tawa
				Art Unit	1623
				Examiner Name	Jonathan S. Lau
				Attorney Docket Number	TPI.2900C3XC2
Sheet	9	of	39		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F25	WO 2004/054571 A1	07-01-2004	Cilag AG	All	
	F26	WO 2004/078161 A1	09-16-2004	Transform Pharmaceuticals, Inc.	All	
	F27	WO 2004/078163 A2	09-16-2004	Transform Pharmaceuticals, Inc.	All	
	F28	WO 2004/089313 A2	10-21-2004	Transform Pharmaceuticals, Inc.	All	
	F29	WO 2005/023198 A2	03-17-2005	Transform Pharmaceuticals, Inc.	All	
	F30	WO 2005/037424 A1	04-28-2005	Salvias AG	All	
	F31	WO 2005/055983 A2	06-23-2005	Medcrystalforms, LCC	All	
	F32	WO 2005/060968 A1	07-07-2005	Sepracor, Inc.	All	
	F33	WO 2005/089375 A2	09-29-2005	S.S.C.I., Inc.	All	
	F34	WO 2005/094804 A1	10-13-2005	The Regents of the University of Michigan	All	
	F35	WO 2006/024930 A1	03-09-2006	Pharmacia and Upjohn Co., LCC	All	
	F36	WO 03/070738 A2	08-28-2003	Transform Pharmaceuticals, Inc.	All	
	F37	WO 03/074474 A2	09-12-2003	Univ. South Fl	All	
	F38	WO 95/17407 A1	06-29-1995	Schering Corp	All	

Examiner Signature	/Jonathan Lau/	Date Considered	04/13/2010
-----------------------	----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./**

J:\TPI\2900C3XC2\PTOIDS-form-suppl.doc\DNB/jb

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet 10 of 39

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F39	WO 00/72841 A1	12-07-2000	Berlant, Jeffrey	All	
	F40	WO 03/033462 A2	04-23-2003	Regents of Univ. Mich.	All	
	F41	WO 01/51919 A2	07-19-2001	Transform Pharm. Inc.	All	
	F42	WO 01/42222 A1	06-14-2001	Pharmacia Corp.	All	
	F43	WO 00/32189 A1	06-08-2000	G. D. Searle & Co.	All	
	F44	WO 01/41760 A3	06-14-2001	Pharmacia Corporation	All	
	F45	WO 01/78724 A1	10/25/2001	Pharmacia Corporation	All	
	F46	WO 01/91750 A1	12/06/2001	Pharmacia Corporation	All	
	F47	WO 02/00627 A1	01/03/2002	Fako Ilaclari A.S.	All	
	F48	IN 182620	12-24-1994	Bajaj <i>et al.</i>	All	
	F49	WO 02/056878 A2	07-25-2002	Pharmacia Corp.	All	
	F50	WO 01/41536 A2	06-14-2001	Pharmacia Corp.	All	
	F51	EP 1167355 A1	01-02-2002	Fako Ilaclari A.S.	All	
	F52	WO 01/42221 A1	06-14-2001	Pharmacia Corp.	All	
	F53	JP 46-33588	10-01-1971	Sanzu Inc.	All	
	F54	WO 00/07583 A2	02-17-2000	Brookhaven Science Associates	All	
	F55	GB 2 169 601	07-16-1986	Tate & Lyle Public Limited Co.	All	
	F56	GB 1 297 261	12-22-1972	E.R. Squibb & Sons, Inc.	All	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet 11 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	AAKERÖY, C. <i>et al.</i> "Crystal engineering of hydrogen-bonded assemblies- a progress report" <i>Aust. J. Chem.</i> , 2001, pp. 409-421, Vol. 54.	
	R2	BINGHAM, A. <i>et al.</i> "Over one hundred solvates of sulfathiazole" <i>Chem. Commun.</i> , 2001, pp. 603-604.	
	R3	BYRIEL, K., <i>et al.</i> "Molecular cocrystals of carboxylic acids. IX. Carboxylic acid interactions with organic heterocyclic bases. The crystal structures of the adducts of (2,4-dichlorophenoxy) acetic acid with 3-hydroxypyridine, 2,4,6-trinitrobenzoic acid with 2-aminopyrimidine, and 4-nitrobenzoic acid with 3-amino-1,2,4-triazole" <i>Aust. J. Chem.</i> , 1992, pp. 969-981, Vol. 45, No. 6.	
	R4	SALMON, J. <i>et al.</i> "Supramolecular chemistry of boronic acids (Abstract)" 38 <sup>th</sup> Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
	R5	URBINA, J. <i>et al.</i> "Supramolecular design of inorganic/organic networks using flexible ligands with self-complementary hydrogen bonds (Abstract)" 38 <sup>th</sup> Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
	R6	SMITH, D. <i>et al.</i> "Structure confirmation by single crystal X-ray diffraction of a series of new schiff bases and theoretical computations on 3-(N-2- $\alpha$ , $\alpha$ , $\alpha$ -trifluorotoluylidene amino) tetrahydrothiophene-1, 1-dioxide (Abstract)" 216 <sup>th</sup> ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.	
	R7	DESIRAJU, G. "Supramolecular synthons in crystal engineering- A new organic synthesis" <i>Angew. Chem. Int. Ed. Engl.</i> , 1995, pp. 2311-2327, Vol. 34.	
	R8	FRITCHIE, C. <i>et al.</i> "The configuration of phenothiazine in various molecular complexes" <i>Chem. Commun.</i> , 1968, pp. 833-834.	
	R9	HUANG, C.-M. <i>et al.</i> "Molecular packing modes. Part XI. Crystal structures of the 2:1 complexes of benzamide with succinic acid and furamide with oxalic acid" <i>J. Chem. Soc. Perkins Trans. 2: Physical Organic Chemistry</i> , 1973, pp. 503-508, Vol. 5.	
	R10	JACKISCH, M. <i>et al.</i> "Structures of three related biphenyl compounds: 4,4'-biphenyldiol, 3,3',5,5'-tetra- <i>tert</i> -butyl-4,4'-biphenyldiol, and 3,3',5,5'- tetra- <i>tert</i> -butyl-1,1'-bicyclohexa-2,5-dienylidene-4,4'-dione" <i>Acta Cryst.</i> , 1990, pp. 919-922, Vol. C46.	
	R11	KIM, S. <i>et al.</i> "The structure of a crystalline complex containing one phenobarbital molecule and two adenine derivatives" <i>Proc. Natl. Acad. Sci. USA</i> , 1968, pp. 402-408, Vol. 60.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet 12 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R12	KOBAYASHI, H. <i>et al.</i> "Sinusoidal structure of the 1:1 complex of phenothiazine and 7,7,8,8-tetracyanoquinodimethane, PTZ-TCNQ" <i>Acta Cryst.</i> , 1974, pp. 1010-1017, Vol. B30.	
	R13	ERMER, O. <i>et al.</i> "Molecular recognition among alcohols and amines: super-tetrahedral crystal architectures of linear diphenol-diamine complexes and aminophenols" <i>J. Chem. Soc. Perkins Trans. 2</i> , 1994, pp. 925-944.	
	R14	MARTIN, R. <i>et al.</i> "Polyphenal-caffeine complexation" <i>J. Chem. Soc., Chem. Commun.</i> , 1986, pp. 105-106.	
	R15	LEHN, J.-M. <i>et al.</i> "Molecular recognition directed self-assembly of ordered supramolecular strands by cocrystallization of complementary molecular components" <i>Chem. Soc., Chem. Commun.</i> , 1990, pp. 479-481.	
	R16	LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XV Preparation and characterization of heterocyclic base adducts with a series of carboxylic acids, and the crystal structures of the adducts of 2-aminopyrimidine with 2,6-dihydroxybenzoic acid, 4-aminobenzoic acid, phenoxyacetic acid, (2,4-dichlorophenoxy) acetic acid, (3,4-dichlorophenoxy)- acetic acid and salicylic acid, and 2-aminopyridine with 2,6-dihydroxybenzoic acid" <i>Aust. J. Chem.</i> , 1994, pp. 1097-1115, Vol. 47.	
	R17	MCINTOSH, J. <i>et al.</i> "Chemotherapeutic drugs in anaerobic infections of wounds" <i>The Lancet</i> , June 26, 1943, pp. 793-795.	
	R18	MCINTOSH, J. <i>et al.</i> "Zinc peroxide, proflavine and penicillin in experimental <i>cl. welchii</i> infections" <i>The Lancet</i> , December 26, 1942, pp. 750-752.	
	R19	SMITH, G. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXI The role of secondary group interactions in adduct formation between 2-aminopyrimidine and substituted benzoic acids: the crystal structures of the adducts with o-phthalic acid, o-nitrobenzoic acid, o-aminobenzoic acid and m-aminobenzoic acid" <i>Aust. J. Chem.</i> , 1995, pp. 1151-1166, Vol. 48.	
	R20	WEISSBUCH, I. <i>et al.</i> "Crystal morphology control with tailor-made additives; a stereochemical approach" <i>Advances in Crystal Growth Research</i> , 2001, pp. 381-400.	
	R21	MCMAHON, J. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. 3 <sup>1</sup> . Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical co-crystals" <i>Z. Kristallogr.</i> , 2005, pp. 340-350, Vol. 220.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

Sheet 13 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R22	MEEJOO, S. <i>et al.</i> "The interplay of aryl-perfluoroaryl stacking interactions and interstack hydrogen bonding in controlling the structure of a molecular cocrystal" <i>Chemphyschem</i> , 2003, pp. 766-769, Vol. 4.	
	R23	MIRMEHRABI, M. <i>et al.</i> "Improving the filterability and solid density of ranitidine hydrochloride form 1" <i>Journal of Pharmaceutical Sciences</i> , July 2004, pp. 1692-1700, Vol. 93, No. 7.	
	R24	MORRIS, K. <i>et al.</i> "Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 91-114, Vol. 48.	
	R25	NAKANISHI, I. <i>et al.</i> "X-ray structural studies on two forms of $\beta$ -cyclodextrin barbitol complexes" <i>Journal of Inclusion Phenomena</i> , 1984, pp. 689-699, Vol. 2.	
	R26	NAKAO, S. <i>et al.</i> "The crystal and molecular structure of the 2:1 molecular complex of theophylline with phenobarbital" <i>Acta Cryst.</i> , 1977, pp. 1373-1378, Vol. B33.	
	R27	NATARAJAN, S. <i>et al.</i> "Reinvestigation of the crystal structure of diglycine hydrochloride" <i>Zeitschrift für Kristallographie</i> , 1992, pp. 265-270, Vol. 198.	
	R28	OLENIK, B. <i>et al.</i> "Cooperative and anticooperative effects in the cocrystals of mono- and diazanaphthalenes with <i>meso</i> -1, 2-diphenyl-1,2-ethanediol" <i>Crystal Growth &amp; Design</i> , 2003, pp. 175-181, Vol. 3, No. 2.	
	R29	OLENIK, B. <i>et al.</i> "Supramolecular synthesis by cocrystallization of oxalic and fumaric acid with diazanaphthalenes" <i>Crystal Growth &amp; Design</i> , 2003, pp. 183-188, Vol. 3, No. 2.	
	R30	GROTH, P. " <i>d</i> -Glucose-sodium chloride-monohydrate (glucose-sodium chloride) = $2C_6H_{12}O_6 \cdot NaCl \cdot H_2O$ " <i>Chemische Krystallographie</i> , 1910, pp. 438-439.	x
	R31	OSWALD, I. <i>et al.</i> "Rationalisation of co-crystal formation through knowledge-mining" <i>Crystallography Reviews</i> , 2004, pp. 57-66, Vol. 10, No. 1.	
	R32	OUYANG, X. <i>et al.</i> "Single-crystal-to-single-crystal topochemical polymerizations of a terminal diacetylene: two remarkable transformations give the same conjugated polymer" <i>J. Am. Chem. Soc.</i> , 2003, pp. 12400-12401, Vol. 125.	
	R33	PATEL, U. <i>et al.</i> "Structure of the 1:1 complex between 4-amino- <i>N</i> -(4,6-dimethyl-2-pyrimidinyl)- benzenesulfonamide (sulfadimidine) and 2-hydroxybenzoic acid (salicylic acid)" <i>Acta Cryst.</i> , 1988, pp. 1264-1267, Vol. C44.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

Sheet 14 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R34	REDDY, L. <i>et al.</i> "Phenyl-perfluorophenyl synthon mediated cocrystallization of carboxylic acids and amides" <i>Crystal Growth &amp; Design</i> , 2004, pp. 89-94, Vol. 4., No. 1.	
	R35	REMENAR, J. <i>et al.</i> "Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids" <i>J. Am. Chem. Soc.</i> , 2003, pp. 8456-8457, Vol. 125.	
	R36	SCHMIDT, G. "Photodimerization in the solid state" <i>Pure Appl. Chem.</i> , 1971, pp. 647-678, Vol. 27.	
	R37	SHAN, N. <i>et al.</i> "Co-crystal of 4,7-phenanthroline and carboxylic acids: synthon competition and prediction" <i>Tetrahedron Letters</i> , 2002, pp. 8721-8725, Vol. 43.	
	R38	SHAN, N. <i>et al.</i> "Crystal engineering using 4,4'-bipyridyl with di- and tricarboxylic acids" <i>Crystal Engineering</i> , 2002, pp. 9-24, Vol. 5.	
	R39	SHAN, N. <i>et al.</i> "Supramolecular synthons in the co-crystal structures of 2-aminopyrimidine with diols and carboxylic acids" <i>Tetrahedron Letters</i> , 2002, pp. 3101-3104, Vol. 43.	
	R40	MCINTOSH, J. <i>et al.</i> "Further observations on the chemotherapy of experimental gas gangrene: flavazole, marfanil, V187 and V335" <i>British Journal of Experimental Pathology</i> , 1946, pp. 46-54, Vol. 27.	
	R41	SHAVIV, R. <i>et al.</i> "Magnetochemistry of the tetrahaloferrate (III) ions 6. Crystal structure and magnetic ordering in [(pyH) <sub>3</sub> Cl] [FeCl <sub>4</sub> ] <sub>2</sub> " <i>Inorganica Chimica Acta</i> , 1992, pp. 613-621, Vol. 198-200.	
	R42	SHEFTER, E. "Structural studies on complexes IV: Crystal structure of a 1:1 5-chlorosalicylic acid and theophylline complex" <i>Journal of Pharmaceutical Sciences</i> , 1969, pp. 710-714, Vol. 58.	
	R43	SHIMIZU, N. <i>et al.</i> "Structure of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine-5,5-diethylbarbituric acid (1:1)" <i>Acta Cryst.</i> , 1982, pp. 2309- 2311, Vol. B38.	
	R44	SINGH, N. B. <i>et al.</i> "Solid state reaction between 8-hydroxyquinoline and <i>p</i> -nitrobenzoic acid" <i>Indian Journal of Chemistry</i> , May 1988, pp. 429-432, Vol. 37B.	
	R45	SMITH, G. <i>et al.</i> "The 1:1 adduct of 4-aminobenzoic acid with 4-aminobenzonitrile" <i>Acta Cryst.</i> , 2000, pp. 1155-1156, Vol. C56.	
	R46	STEINER, T. "Donor and acceptor strengths in C-H...O hydrogen bonds quantified from crystallographic data of small solvent molecules" <i>New. J. Chem.</i> , 1998, pp. 1099-1103.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

15

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R47	STOREY, R. et al. "Automation of solid form screening procedures in the pharmaceutical industry- how to avoid the bottlenecks" <i>Crystallography Reviews</i> , 2004, pp. 45-56, Vol. 10, No. 1.	
	R48	SZAFRAN, M. et al. "Molecular structures and hydrogen bonding in the 1:1 and 1:2 complexes of pyridine betaine with 2,6-dichloro-4-nitrophenol; an example of strongly coupled hydrogen bonds, O-H...O=C-O-H...O." <i>Journal of Molecular Structure</i> , 1997, pp. 145-160, Vol. 416.	
	R49	TAKEUCHI, M. et al. "Synchrotron radiation SAXSWAXS study of polymorph-dependent phase behavior of binary mixtures of saturated monoacid triacylglycerols" <i>Crystal Growth &amp; Design</i> , 2003, pp. 369-374, Vol. 3, No. 3.	
	R50	TANG, C. P. et al. "Reaction pathways in crystalline host-guest inclusion complexes: rotation by a net 180° of the acetyl group on photoaddition of guest- acetophenone and -m-Chloroacetophenone to the atom C5 of host deoxycholic acid" <i>J. Am. Chem. Soc.</i> , 1985, pp. 4058-4070, Vol. 107.	
	R51	TAYLOR, R. et al. "Rules governing the crystal packing of mono- and dialcohols" <i>Acta Crystallographica Section B, Structural Science</i> , 2001, pp. 815-827, Vol. B57.	
	R52	THALLAPALLY, P. et al. "Polymorphism of 1,3,5-trinitrobenzene induced by a trisindane additive" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 1149-1155, Vol. 43.	
	R53	TIMMERMAN, P. et al. "Noncovalent Assembly of functional groups on calix[4]arene molecular boxes" <i>Chem. Eur. J.</i> , 1997, pp. 1823-1832, Vol. 3., No. 11.	
	R54	SHAN, N. et al. "Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics" <i>Chem. Commun.</i> , 2002, pp. 2372-2373.	
	R55	CAIRA, M. et al. "X-ray structure and thermal analysis of a 1:1 complex between (S)-naproxen and heptakis (2,3,6-tri-O-methyl)-β-cyclodextrin" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1995, pp. 277-290, Vol. 20.	
	R56	TRASK, A. et al. "Crystal engineering of organic cocrystals by the solid-state grinding approach" <i>Top Curr. Chem.</i> , 2005, pp. 41-70, Vol. 254.	
	R57	TRASK, A. et al. "Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration" <i>Crystal Growth &amp; Design</i> , 2005, pp. 1013-1021, Vol. 5, No. 3.	
	R58	TRASK, A. et al. "Solvent-drop grinding: green polymorph control of cocrystallisation" <i>Chem. Commun.</i> , 2004, pp. 890-891 in addition to supplemental materials.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

16

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R59	TROWBRIDGE, L. <i>et al.</i> "Composites for nonlinear optics: Crystal growth and polymorphism" <i>University of Sussex, Falmer Brighton UK, School of Chemistry and Molecular Sciences</i> , pp. 272. <b>Abstr. Pap., Am. Chem. Soc. 1994, vol. 208</b>	
	R60	UNO, T. <i>et al.</i> "Structure of 5,5-diphenylhydantoin-1- (4-bromophenyl)-4-dimethylamino-2,3-dimethyl-3-pyrazolin-5-one (1:1)" <i>Acta Cryst.</i> , 1980, pp. 2794-2796, Vol. B36.	
	R61	VAN ROEY, P. <i>et al.</i> "Structure-activity studies of non-steroidal aromatase inhibitors: the crystal and molecular structures of CGS 16949A and CGS 18320B" <i>J. Enzyme Inhibition</i> , 1991, pp. 119-132, Vol. 5.	
	R62	VAN ROEY, P. <i>et al.</i> "Structure of <i>cis</i> -1-[[4-(1-imidazolylmethyl) cyclohexyl] methyl] imidazole- succinic acid complex" <i>Acta Cryst.</i> , 1991, pp. 1015-1018, Vol. C47.	
	R63	VISHWESHWAR, P. <i>et al.</i> "Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients" <i>Chem. Commun.</i> , 2005, pp. 4601-4603.	
	R64	VISHWESHWAR, P. <i>et al.</i> "Recurrence of carboxylic acid- pyridine supramolecular synthon in the crystal structures of some pyrazinecarboxylic acids" <i>J. Org. Chem.</i> , 2002, pp. 556-565, Vol. 67.	
	R65	VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons based on N-H...N and C-H...O hydrogen bonds. Crystal engineering of a helical structure with 5,5-diethylbarbituric acid" <i>Chem. Commun.</i> , 2002, pp. 1830-1831.	
	R66	VISHWESHWAR, P. <i>et al.</i> "Supramolecular synthons in phenol-isonicotinamide adducts" <i>Cryst. Eng. Comm.</i> 2003, pp. 164-168, Vol. 5, No. 31.	
	R67	VOET, D. <i>et al.</i> "The crystal and molecular structure of the intermolecular complex 9-ethyladenine-5, 5-diethylbarbituric acid" <i>Journal of the American Chemical Society</i> , November 15, 1972, pp. 8213-8222, Vol. 94, No. 23.	
	R68	VOET, D. <i>et al.</i> "The structure of an intermolecular complex between cytosine and 5-fluorouracil" <i>Journal of the American Chemical Society</i> , May 21, 1969, pp. 3069-3075, Vol. 91, No. 11.	
	R69	STEZOWSKI, J. J. <i>et al.</i> "Characterization of a 1:1 complex of an unusual structure in the phenothiazine/phenazine binary phase diagram" <i>Zeitschrift fur Kristallographie in International Journal for Structural, Physical, Chemical Aspects of Crystalline Materials</i> , 1983, pp. 213-215, Vol. 162, No. 1-4.	X
	R70	WANG, A. <i>et al.</i> "Crystal structure of 1:1 complex of barbital with 1-methylimidazole" <i>Journal of Pharmaceutical Sciences</i> , March 1979, pp. 361-363, Vol. 68, No. 3.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

Sheet

17

of

39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R71	ALBEROLA, S. <i>et al.</i> "Crystalline and Molecular Structure of Sulfanilimide-Antipyrine" <i>Acta Cryst.</i> , 1977, pp. 3337-3341, Vol. B33.	X
	R72	WOOD, R. A. <i>et al.</i> "2,5-O-methylene-D-mannitol sodium-chloride, C <sub>7</sub> H <sub>14</sub> O <sub>6</sub> . NaCl" <i>Cryst. Struct. Comm.</i> , 1976, 207-210, Vol. 5.	
	R73	XU, J. <i>et al.</i> "Effect of composition distribution on miscibility and co-crystallization phenomena in the blends of low density polyethylene with conventional and metallocene-based ethylene-butene copolymers" <i>Polymer</i> , 2001, pp. 3867-3874, Vol. 42.	
	R74	YOO, J. <i>et al.</i> "Cocrystallization of a dinuclear platinum complex as a monomer and a one-dimensional polymer" <i>Polyhedron</i> , 2002, pp. 715-719, Vol. 21.	
	R75	ZAITU, S. <i>et al.</i> "A 2:1 molecular complex of theophylline and 5-fluorouracil as the monohydrate" <i>Acta Cryst.</i> , 1995, pp. 1857-1859, Vol. C51.	
	R76	ZAMAN, M. B. <i>et al.</i> "Linear hydrogen-bonded molecular tapes in the cocrystals of squaric acid with 4,4'-dipyridylacetylene and 1,2-bis(4-pyridyl) ethylene" <i>Acta Cryst.</i> , 2001, pp. 621-624, Vol. C57.	
	R77	ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: hydrogen-bonded molecular "tapes" <sup>1</sup> " <i>J. Am. Chem. Soc.</i> , 1990, pp. 9025-9026, Vol. 112.	
	R78	ZERKOWSKI, J. <i>et al.</i> "Investigations into the robustness of secondary and tertiary architecture of hydrogen-bonded crystalline tapes" <i>Chem. Mater.</i> , 1994, pp. 1250-1257, Vol. 6.	
	R79	ZERKOWSKI, J. <i>et al.</i> "New varieties of crystalline architecture produced by small changes in molecular structure in tape complexes of melamines and barbiturates" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4305-4315, Vol. 116.	
	R80	ZERKOWSKI, J. <i>et al.</i> "Polymorphic packing arrangements in a class of engineered organic crystals" <i>Chem. Mater.</i> , 1997, pp. 1933-1941, Vol. 9.	
	R81	ZERKOWSKI, J. <i>et al.</i> "Solid-state structures of "Rosette" and "Crinkled Tape" motifs derived from the cyanuric acid-melamine lattice" <i>J. Am. Chem. Soc.</i> , 1992, pp. 5473-5475, Vol. 114.	
	R82	ZHANG, R. <i>et al.</i> "Atmospheric new particle formation enhanced by organic acids" <i>Science</i> , June 4, 2004, pp. 1487-1490 with additional supporting online material, Vol. 304.	
	R83	ZHU, H. <i>et al.</i> "Influence of water activity in organic solvent + water mixtures on the nature of the crystallizing drug phase. 1. theophylline" <i>International Journal of Pharmaceutics</i> , 1996, pp. 151-160, Vol. 135.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

Sheet

18

of

39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R84	CHANG, Y. <i>et al.</i> "An Approach to the Design of Molecular Solids. Strategies for Controlling the Assembly of Molecules into Two-Dimensional Layered Structures" <i>J. Am. Chem. Soc.</i> , 1993, pp. 5991-6000, Vol. 115.	
	R85	COWAN, J. A. <i>et al.</i> "Neutron diffraction studies of the 1:1 and 2:1 cocrystals of benzene-1,2,4,5-tetracarboxylic acid and 4,4'-bipyridine" <i>Acta Cryst.</i> , 2006, pp. o157-o161, Vol. C62.	
	R86	DAVIES, N. M. <i>et al.</i> "Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib. A Selective Cyclo-Oxygenase-2 Inhibitor" <i>Clin. Pharmacokinet.</i> , March 2000, pp. 225-242, Vol. 38, No. 3.	
	R87	DESIRAJU, G.R. "Solid-State Chemistry: Crystal Gazing: Structure Prediction and Polymorphism" <i>Science</i> , October 17, 1997, pp. 404-405, Vol. 278, No. 5337.	
	R88	DOELKER, E. "Physicochemical behavior of active substances. Consequences for the feasibility and stability of pharmaceutical forms" <i>STP Pharma Pratiques</i> , 1999, pp. 399-409, Vol. 9, No.5.	
	R89	DOELKER, E. "Crystalline modifications and polymorphism changes during drug manufacturing" <i>Annales Pharmaceutiques Francaises</i> , 2002, pp. 161-176, Vol. 60, No. 3.	
	R90	DUNITZ, J. D. "Are crystal structures predictable?" <i>Chem Commun.</i> , 2003, pp. 545-548.	
	R91	FEYNMAN, R. P. "There's Plenty of Room at the Bottom" <i>Engineering and Science</i> , February 1960, pp. 22-36.	
	R92	JAIN, N. K. <i>et al.</i> "Polymorphism in Pharmacy" <i>Indian Drugs</i> , 1986, pp. 315-329, Vol. 23, No. 6.	
	R93	BALL, P. "Scandal of crystal design..." <i>Nature</i> , June 20, 1996, pp. 648-650, Vol. 381.	
	R94	BASTIN, R. J. <i>et al.</i> "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities" <i>Organic Process Research &amp; Development</i> , 2000, pp. 427-435, Vol. 4, No. 5.	
	R95	BERNSTEIN, J. <i>et al.</i> "Concomitant Polymorphs" <i>Angew. Chem. Int. Ed.</i> , 1999, pp. 3440-3461, Vol. 38.	
	R96	BOUCHER, E. <i>et al.</i> "Use of Hydrogen Bonds to Control Molecular Aggregation. Behavior of Dipyridones and Pyridone-Pyrimidones Designed to Form Cyclic Triplexes" <i>J. Org. Chem.</i> , 1995, pp. 1408-1412, Vol. 60.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet 19 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R97	KIRCHNER, M. T. <i>et al.</i> , Co-crystals with Acetylene: Small is not Simple!" <i>Chem. Eur. J.</i> , 2010, pp. 2131-2146, Vol. 16.	
	R98	MOULTON, B. <i>et al.</i> "From Molecules to Crystal Engineering: Supramolecular Isomerism and Polymorphism in Network Solids" <i>Chem. Rev.</i> , 2001, pp. 1629-1658, Vol. 101.	
	R99	MUZAFFAR, N. A. <i>et al.</i> "Polymorphism and Drug Availability" <i>Journal of Pharmacy</i> , 1979, pp. 59-66, Vol. 1, No. 1.	
	R100	OSORIO-LOZADA, A. <i>et al.</i> "Synthesis and determination of the absolute stereochemistry of the enantiomers of adrafinil and modafinil" <i>Tetrahedron: Asymmetry</i> , 2004, pp. 3811-3815, Vol. 15.	
	R101	OTSUKA, M. <i>et al.</i> "Effect of Polymorphic Forms of Bulk Powders on Pharmaceutical Properties of Carbamazepine Granules" <i>Chem. Pharm. Bull.</i> , 1999, pp. 852-856, Vol. 47, No. 6.	
	R102	SHATTOCK, T. R. <i>et al.</i> "Hierarchy of Supramolecular Synthons: Persistent Carboxylic Acid...Pyridine Hydrogen Bonds in Cocrystals That also Contain a Hydroxyl Moiety" <i>Cryst. Growth Des.</i> , 2008, pp. 4533-4545, Vol. 8, No. 12.	
	R103	THAYER, A. M. "Form and Function: The choice of pharmaceutical crystalline form can be used to optimize drug properties, and cocrystals are emerging as new alternatives" <i>Chemical &amp; Engineering News</i> , June 18, 2007, pp. 17-30, Vol. 85, No. 25.	
	R104	VILLA, L. A. <i>et al.</i> "Central Nervous System Paracoccidioidomycosis. Report of a Case Successfully Treated with Itraconazol" <i>Rev. Inst. Med. Trop. S. Paulo</i> , July-August 2000, pp. 231-234, Vol. 42, No. 4.	
	R105	ZAWOROTKO, M. J. "Crystal Engineering of Diamondoid Networks" <i>Chemical Society Reviews</i> , 1994, pp. 283-288, Vol. 23.	
	R106	KLEIN, C. L. <i>et al.</i> "Molecular Structure of Two Conformationally Restrained Fentanyl Analogues: cis- and trans-Isomers of N-{3-Methyl-1-[2-(1,2,3,4-tetrahydro)naphthyl]-4-piperidinyl}-N-phenylpropanamide" <i>Journal of Pharmaceutical Sciences</i> , November 1985, pp. 1147-1151, Vol. 74, No. 11.	
	R107	WUNDERLICH, H. F. <i>et al.</i> "The Derivatives of carbamazepine with ammonium halogenides and formamide" <i>Pharmazie</i> , 1991, pp. 507-509, Vol. 46, No. 7.	
	R108	EL-NAHHAS, S. A. "Physico-chemical characteristics of carbamazepine- $\beta$ -cyclodextrin inclusion compounds and carbamazepine-PEG solid dispersions" <i>Pharmazie</i> , 1996, pp. 960-963, Vol. 51, No. 12.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

20

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R109	REYNOLDS, J. E. F. (ed). Martindale, The Extra Pharmacopoeia, 1993, The Pharmaceutical Press, London, England, 13 <sup>th</sup> edition, p. 1610.	
	R110	PEDIREDDI, V. R. <i>et al.</i> "Layered Structures Formed by Dinitrobenzoic Acids" <i>Tetrahedron Letters</i> , 1998, pp. 9831-9834, Vol. 39.	
	R111	ZAMAN, M. B. <i>et al.</i> "Crystal Engineering Using Anilic Acids and Dipyridyl Compounds through a New Supramolecular Synthon" <i>J. Org. Chem.</i> , 2001, pp. 5987-5995, Vol. 66.	
	R112	Japanese Notice of Reasons for Rejection dated October 8, 2009, Japanese Application No. 2003-572946.	
	R113	AAKERÖY, C. <i>et al.</i> "Aromatic dicarboxylic acids as building blocks of extended hydrogen-bonded architectures" <i>Supramolecular Chemistry</i> , 1998, pp. 127-135, Vol. 9.	
	R114	AAKERÖY, C. <i>et al.</i> "Assembly of 2-D inorganic/organic lamellar structures through a combination of copper (I) coordination polymers and self-complimentary hydrogen bonds" <i>J. Chem. Soc., Dalton Trans.</i> , 2000, pp. 3869-3872.	
	R115	AAKERÖY, C. <i>et al.</i> "Building organic assemblies with 2-pyridone and dicarboxylic acids: relating molecular conformation and synthon stability to crystal structure" <i>Crystal Engineering</i> , 1998, pp. 225-241, Vol. 1, No. 3-4.	
	R116	AAKERÖY, C. <i>et al.</i> "The C-H...C1 hydrogen bond: does it exist?" <i>New J. Chem.</i> , 1999, pp. 145-152.	
	R117	AAKERÖY, C. <i>et al.</i> "Crystal engineering of ionic solids" <i>Modular Chemistry</i> (ed. by Michl, J.), 1997, pp. 153-162, Kluwer Academic Publishers, The Netherlands.	
	R118	AAKERÖY, C. <i>et al.</i> "Crystal engineering: strategies and architectures" <i>Acta Cryst.</i> , 1997, pp. 569-586, Vol. B53.	
	R119	AAKERÖY, C. <i>et al.</i> "Crystal engineering using intermolecular hydrogen-bonded connectors and classic coordination chemistry" <i>Transactions ACA</i> , 1998, pp. 97-103, Vol. 33.	
	R120	AAKERÖY, C. <i>et al.</i> "The crystal structure of the molecular cocrystal L-malic acid L-tartaric acid (1/1)" <i>Supramolecular Chemistry</i> , 1996, pp. 153-156, Vol. 7.	
	R121	AAKERÖY, C. <i>et al.</i> "Deliberate combination of coordination polymers and hydrogen bonds in a supramolecular design strategy for inorganic/organic hybrid networks" <i>Chem. Commun.</i> , 2000, pp. 935-936.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

21

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R122	AKAZOME, M. <i>et al.</i> "Enantioselective inclusion of methyl phenyl sulfoxides and benzyl methyl sulfoxides by (R)-phenylglycyl-(R)-phenylglycine and the crystal structures of the inclusion cavities" <i>J. Org. Chem.</i> , 2000, pp. 68-76, Vol. 65.	
	R123	AKHTARUZZAMAN, M.D. <i>et al.</i> "One-dimensional hydrogen-bonded molecular tapes in 1, 4-bis[(4-pyridinio) ethynyl]benzene chloranilate" <i>Acta. Cryst.</i> , 2001, pp. o353-o355, Vol. E57.	
	R124	ALLEN, F. <i>et al.</i> "Systematic analysis of structural data as a research technique in organic chemistry" <i>Acc. Chem. Res.</i> , 1983, pp. 146-153, Vol. 16.	
	R125	ALMARSSON, Ö. <i>et al.</i> "Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?" <i>Chem. Commun.</i> , 2004, pp. 1889-1896.	
	R126	AMAI, M. <i>et al.</i> "1:1 complex of octadecanoic acid and 3-pyridinecarboxamide" <i>Acta Cryst.</i> , 1998, pp. 1367-1369, Vol. C54.	
	R127	ANDERSON, N. <i>et al.</i> "Sulfonation with inversion by mitsunobu reaction: an improvement on the original conditions" <i>J. Org. Chem.</i> , 1996, pp. 7955-7958, Vol. 61.	
	R128	AOKI, K. <i>et al.</i> "A 1:1 complex of theophylline and <i>p</i> -nitrophenol" <i>Acta Cryst.</i> , 1978, pp. 2333-2336, Vol. B34.	
	R129	ASHTON, P. <i>et al.</i> "Combining different hydrogen-bonding motifs to self-assemble interwoven superstructures" <i>Chem. Eur. J.</i> , 1998, pp. 577-589, Vol. 4, No. 4.	
	R130	BARKER, P. A. <i>et al.</i> "Effect of crystallization temperature on the cocrystallization temperature on the cocrystallization of hydroxybutyrate/ hydroxyvalerate copolymers" <i>Polymer</i> , pp. 913-919, Vol. 38, No. 4.	
	R131	BERKOVITCH-YELLIN, Z. <i>et al.</i> "Electron density distribution in cumulenes: an x-ray study of the complex allenedicarboxylic acid- acetamide (1:1) at -150° C" <i>Acta Cryst.</i> , 1977, pp. 3670-3677, Vol. B33.	
	R132	BERKOVITCH-YELLIN, Z. <i>et al.</i> "The role played by C-H...O and C-H...N interactions in determining molecular packing and conformation" <i>Acta Cryst.</i> , 1984, pp. 159-165, Vol. B40.	
	R133	BERL, V. <i>et al.</i> "Induced fit selection of a barbiturate receptor from a dynamic structural and conformational/configurational library" <i>Eur. J. Org. Chem.</i> , 1999, pp. 3089-3094.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet	22	of	39
-------	----	----	----

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R134	BERTOLASI, V. <i>et al.</i> "Competition between hydrogen bonding and donor-acceptor interactions in co-crystals of 1,3-dimethylbarbituric acid with aromatic amines" <i>New J. Chem.</i> , 2001, pp. 408-415, Vol. 25.	
	R135	BERTOLASI, V. <i>et al.</i> "General rules for the packing of hydrogen-bonded crystals as derived from the analysis of squaric acid anions: aminoaromatic nitrogen base co-crystals" <i>Acta Cryst.</i> , 2001, pp. 591-598, Vol. B57.	
	R136	BETTINETTI, G. <i>et al.</i> "Structure and solid-state chemistry of anhydrous and hydrated crystal forms of the trimethoprim-sulfamethoxypyridazine 1:1 molecular complex" <i>Journal of Pharmaceutical Sciences</i> , April 2000, pp. 478-489, Vol. 89, No. 4.	
	R137	BETTINETTI, G. <i>et al.</i> "Thermal analysis of binary systems of the pharmaceuticals trimethoprim and benzoic acid" <i>Journal of Thermal Analysis</i> , 1983, pp. 285-294, Vol. 28.	
	R138	BETTIS, J. <i>et al.</i> "Biopharmaceutics and dosage form design" <i>Amer. J. Hosp. Pharm.</i> , March 1973, pp. 240-243, Vol. 30.	
	R139	BOLTON, S. <i>et al.</i> "Complexes formed in solution by homologs of caffeine" <i>Journal of the American Pharmaceutical Association</i> , January 1957, pp. 38-41, Vol. XLVI, No. 1.	
	R140	BOND, A. "In situ co-crystallisation as a tool for low-temperature crystal engineering" <i>Chem. Commun.</i> , 2003, pp. 250-251, Vol. 2.	
	R141	BONIN, M. <i>et al.</i> "Urotropin azelate: a rather unwilling co-crystal" <i>Acta Cryst.</i> , 2003, pp. 72-86, Vol. B59.	
	R142	BOSSHARD, C. <i>et al.</i> "Microscopic nonlinearities of two-component organic crystals" <i>J. Opt. Soc. Am. B</i> , November 2001, pp. 1620-1626, Vol. 18, No. 11.	
	R143	GLUZMAN, M. Kh. <i>et al.</i> "Investigation of Eutectic Melting in Systems Composed of Organic Salts and Acids" <i>Journal of Physical Chemistry</i> , 1960, pp. 2742-2747, Vol. 34.	X
	R144	BRAGA, D. <i>et al.</i> "Hydrogen bonding interactions between ions: a powerful tool in molecular crystal engineering" <i>Structure and Bonding</i> , 2004, pp. 1-32, Vol. 111.	
	R145	BRIERLEY, C. <i>et al.</i> "Preparation and structure of the 1:2 $\pi$ -molecular complex of phenothiazine with pyromellitic dianhydride" <i>J. Chem. Phys.</i> , February 1, 1985, pp. 1522-1528, Vol. 82, No. 1.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

23

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R146	BURGI, H. <i>et al.</i> "Crystallisation of supramolecular materials" <i>Current Opinion in Solid State &amp; Materials Science</i> , 1998, pp. 425-430, Vol. 3.	
	R147	BYRN, S. R. <i>et al.</i> "Solid-state pharmaceutical chemistry" <i>Chem. Mater.</i> , 1994, pp. 1148-1158, Vol. 6.	
	R148	CAIRA, M. "Molecular complexes of sulfonamides. Part 1. 1:1 complexes between sulfadimidine [4-amino-N-(4,6-dimethyl-2-pyrimidinyl) benzenesulfonamide] and 2- and 4-aminobenzoic acids" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1991, pp. 641-648, Vol. 21, No. 5.	
	R149	CAIRA, M. "Molecular complexes of sulfonamides. Part 2. 1:1 complexes between drug molecules: sulfadimidine -acetylsalicylic acid and sulfadimidine-4-aminosalicylic acid" <i>Journal of Crystallographic and Spectroscopic Research</i> , 1992, pp. 193-200, Vol. 22, No. 2.	
	R150	CAIRA, M. "Molecular complexes of sulfonamides. 3. Structure of 5-methoxysulfadiazine (Form II) and its 1:1 complex with acetylsalicylic acid" <i>Journal of Chemical Crystallography</i> , 1994, pp. 695-701, Vol. 24, No. 10.	
	R151	CAIRA, M. <i>et al.</i> "Order-disorder enantiotropy, monotropy, and isostructurality in a tetroxoprim-sulfametrole 1:1 molecular complex: crystallographic and thermal studies" <i>Journal of Pharmaceutical Sciences</i> , November 2003, pp. 2164-2176, Vol. 92, No. 11.	
	R152	CAIRA, M. <i>et al.</i> "Selective formation of hydrogen bonded cocrystals between a sulfonamide and aromatic carboxylic acids in the solid state" <i>J. Chem. Soc. Perkin Trans. 2</i> , 1995, pp. 2213-2216.	
	R153	CAIRA, M. <i>et al.</i> "Structure of a 1:1 complex between the anthelmintic drug mebendazole and propionic acid" <i>Journal of Chemical Crystallography</i> , 1998, Vol. 28, No. 1, pp. 11-15.	
	R154	CAMERMAN, A. <i>et al.</i> "Hydrogen bonding interaction of diphenylbarbituric acid and 9-ethyladenine. Crystal structure of a 1:1 complex" <i>Can. J. Chem.</i> , 2000, pp. 1045-1051, Vol. 78.	
	R155	CAMERMAN, A. <i>et al.</i> "Molecular structure of acetylacetone. A crystallographic determination" <i>J. Am. Chem. Soc.</i> , 1983, pp. 1584-1586, Vol. 105, No. 6.	
	R156	CANNON, A. <i>et al.</i> "Noncovalent derivatization: green chemistry applications of crystal engineering" <i>Crystal Growth &amp; Design</i> , 2002, pp. 255-257, Vol. 2, No. 4.	
Examiner Signature	/Jonathan Lau/		Date Considered
			04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

24

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R157	CHINNAKALI, K. <i>et al.</i> "2-aminopyrimidine and <i>p</i> -phenylene-diacetic acid (1:1) co-crystal" <i>Acta Cryst.</i> , 1999, pp. 399-401, Vol. C55.	
	R158	BRADER, M.L. <i>et al.</i> "Hybrid insulin cocrystals for controlled release delivery" <i>Nature Biotechnol.</i> , 2002, 20:800-804.	
	R159	FLEISCHMAN, S.G. <i>et al.</i> "Crystal Engineering of the Composition of Pharmaceutiactal Phases: Multiple-Component Crystalline Solids Involving Carbamazepine" <i>Crystal Growth &amp; Design.</i> , 2003, 3(6):909-919.	
	R160	CHOI, C. <i>et al.</i> "Cocrystallization of melaminium levulinate monohydrate" <i>Acta Cryst.</i> , 2004, pp. o295-o296, Vol. C60.	
	R161	CHOW, Y. P. <i>et al.</i> "Complexation of acetaminophen with methyl xanthines" <i>Journal of Pharmaceutical Sciences</i> , 1972, pp. 1454-1458, Vol. 61.	
	R162	CHRISTIAN, S. <i>et al.</i> "Activity coefficient effects in spectral and solubility studies of molecular complex equilibria" <i>Journal of the American Chemical Society</i> , September 20, 1972, pp. 6861-6862, Vol. 94, No. 19, Communications to the editor.	
	R163	COLL, M. <i>et al.</i> "Molecular structure of the complex formed between the anticancer drug cisplatin and d(pGpG): C222 <sub>1</sub> crystal form" <i>Journal of Biomolecular Structure &amp; Dynamics</i> , 1990, pp. 315-330, Vol. 8, No. 2.	
	R164	COPP, S. <i>et al.</i> "Supramolecular chemistry of [Mn(CO) <sub>3</sub> (μ <sub>3</sub> -OH)] <sub>4</sub> : Assembly of a cubic hydrogen-bonded diamondoid network with 1,2-diamineothane" <i>J. Am. Chem. Soc.</i> , 1992, pp. 8719-8720, Vol. 114.	
	R165	CORDI, A. <i>et al.</i> "(S)-Spiro [(1, 3-diazacyclopent-1-ene)-5, 2' -(7'-methyl-1',2',3',4'-tetrahydronaphthalene)]: resolution, stereospecific synthesis, and preliminary pharmacological characterization as a partial α-adrenergic agonist" <i>J. Med. Chem.</i> , 1997, pp. 2931-2935, Vol. 40.	
	R166	CRAVEN, M. <i>et al.</i> "The 2:1 crystal complex of 5, 5-diethylbarbituric acid (barbital) and caffeine" <i>Acta Cryst.</i> , 1974, pp. 1191-1195, Vol. B30.	
	R167	CRAVEN, M. <i>et al.</i> "The crystal structures of two polymorphs of 5,5'-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1969, pp. 1978-1993, Vol. B25.	
	R168	CUDNEY, B. <i>et al.</i> "Screening and optimization strategies for macromolecular crystal growth" <i>Acta Cryst.</i> , 1994, pp. 414-423, Vol. D50.	
Examiner Signature	/Jonathan Lau/		Date Considered 04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 25 of 39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R169	DATTA, S. <i>et al.</i> "Molecular complex formation between riboflavin and salicylate in an aqueous medium" <i>Bull. Chem. Soc. Jpn.</i> , 2003, pp. 1729-1734, Vol. 76.	
	R170	DAVEY, R. J. <i>et al.</i> "Crystal engineering- nucleation, the key step" <i>Cryst. Eng. Comm.</i> , 2002, pp. 257-264, Vol. 4, No. 47.	
	R171	DAVEY, R. J. <i>et al.</i> "Crystallisation in polymer films: control of morphology and kinetics of an organic dye in a polysilicone matrix" <i>J. Mater. Chem.</i> , 1997, pp. 237-241, Vol. 7, No. 2.	
	R172	DEBERNARDIS, J. <i>et al.</i> "Conformationally defined adrenergic agents. 5. Resolution, absolute configuration, and pharmacological characterization of the enantiomers of 2-(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl) imidazoline: a potent agonist at $\alpha$ -adrenoceptors" <i>J. Med. Chem.</i> , 1987, pp. 1011-1017, Vol. 30.	
	R173	DESIRAJU, G. <i>et al.</i> "Crystal and co-crystal" <i>Cryst. Eng. Comm.</i> , 2003, pp. 466-467, Vol. 5, No. 82.	
	R174	DESIRAJU, G. <i>et al.</i> "Crystal engineering: outlook and prospects" <i>Current Science</i> , October 25, 2001, pp. 1038-1042, Vol. 81, No. 8.	
	R175	DUAX, W. <i>et al.</i> "The structure of the crystalline complex estradiol. Urea (1:1)" <i>Acta Cryst.</i> , 1972, pp. 1864-1871, Vol. B28.	
	R176	DUNITZ, J. "Crystal and co-crystal: a second opinion" <i>Cryst. Eng. Comm.</i> , 2003, pp. 506, Vol. 5, No. 91.	
	R177	DUNITZ, J. "New light on an old story: the solid-state transformation on ammonium cyanate into urea" <i>J. Am. Chem. Soc.</i> , 1998, pp. 13274-13275, Vol. 120.	
	R178	ENRIGHT, G. <i>et al.</i> "Thermally programmable gas storage and release in single crystals of an organic van der Waals host" <i>J. Am. Chem. Soc.</i> , 2003, pp. 9896-9897, Vol. 125.	
	R179	EPSTEIN, R. <i>et al.</i> "The x-ray crystal structure of the molecular complex 8-bromo-9-ethyladenine-5-allyl-5-isobutylbarbituric acid" <i>Acta Cryst.</i> , 1976, pp. 2180-2188, Vol. B32.	
	R180	OSWALD, I.D.H. <i>et al.</i> "The formation of paracetamol (acetaminophen) adducts with hydrogen-bond acceptors" <i>Acta Cryst.</i> , 2002, B58:1057-1066.	
	R181	VISHWESHWAR, P. <i>et al.</i> "Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons, and melting point alternation" <i>Crystal Growth &amp; Design</i> , 2003, pp. 783-790, Vol. 3, No. 5.	
Examiner Signature	/Jonathan Lau/		Date Considered 04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
		Application Number		10/747,742	
		Filing Date		December 29, 2003	
		First Named Inventor		Mark Tawa	
		Group Art Unit		1623	
		Examiner Name		Jonathan S. Lau	
		Attorney Docket Number		TPI.2900C3XC2	
Sheet	26	of	39		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R182	ETTER, M. "Encoding and decoding hydrogen-bond patterns of organic compounds" <i>Acc. Chem. Res.</i> , 1990, pp. 120-126, Vol. 23.	
	R183	ETTER, M. <i>et al.</i> "Graph-set analysis of hydrogen-bond patterns in organic crystals" <i>Acta Cryst.</i> , 1990, pp. 256-262, Vol. B46.	
	R184	ETTER, M. <i>et al.</i> "Hydrogen bond directed cocrystallization and molecular recognition properties of acyclic imides" <i>J. Am. Chem. Soc.</i> , 1991, pp. 2586-2598, Vol. 113.	
	R185	ETTER, M. "Hydrogen bonds as design elements in organic chemistry" <i>J. Phys. Chem.</i> , 1991, pp. 4601-4610, Vol. 95.	
	R186	FABIAN, L. <i>et al.</i> "Volumetric measure of isostructurality" <i>Acta Cryst.</i> , 1999, pp. 1099-1108, Vol. B55.	
	R187	FALLON III, L. "The crystal and molecular structure of 5-fluorouracil" <i>Acta Cryst.</i> , pp. 2549-2556, Vol. B29.	
	R188	FEIBUSH, B. <i>et al.</i> "Chiral separation of heterocyclic drugs by HPLC: solute-stationary phase base-pair interactions" <i>J. Am. Chem. Soc.</i> , 1986, pp. 3310-3318, Vol. 108.	
	R189	FIFER, E. <i>et al.</i> "Fentanyl analogues 3. 2-(1,2,3,4-tetrahydro)-naphthyl substituted 4-anilidopiperidines" <i>Eur. J. Med. Chem.-Chim. Ther.</i> , 1984, pp. 519-524, Vol. 19, No. 6.	
	R190	RECK, G. <i>et al.</i> "Crystal structures of the carbamazepine/ammonium chloride and carbamazepine/ammonium bromide adducts and their transformation into carbamazepine dihydrate" <i>Pharmazie</i> , 1991, pp. 509-512, Vol. 46, No. 7.	X
	R191	FOXMAN, B. M. <i>et al.</i> "Environmentally benign synthesis using crystal engineering: steric accommodation in non-covalent derivatives of hydroquinones" <i>Crystal Engineering</i> , 1998, pp. 109-118, Vol. 1, No. 1.	
	R192	FOXMAN, B. M. <i>et al.</i> "Noncovalent derivatives of hydroquinone: <i>BIS</i> -( <i>N,N</i> -dialkyl) bicyclo[2.2.2]octane-1,4-dicarboxamide complexes" <i>Crystal Engineering</i> , 1999, pp. 55-64, Vol. 2, No. 1.	
	R193	FUJII, S. <i>et al.</i> "Crystal and molecular structure of a 1:1 molecular complex of adenine and riboflavin" <i>Archives of Biochemistry and Biophysics</i> , 1977, pp. 363-370, Vol. 181.	
Examiner Signature		/Jonathan Lau/	
		Date Considered	04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

Sheet	27	of	39
-------	----	----	----

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R194	GAO, X. <i>et al.</i> "Supramolecular construction of molecular ladders in the solid state" <i>Angew. Chem. Int. Ed.</i> , 2004, pp. 232-236, Vol. 43.	
	R195	GARTLAND, G. L. <i>et al.</i> "Hydrogen bonding NH...O=C of barbiturates: the (1:1) crystal complex of urea and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 980-987, Vol. B30.	
	R196	GHOSH, M. "Structure and conformation of the 1:1 molecular complex sulfaproxyline-caffeine" <i>Acta Cryst.</i> , 1991, pp. 577-580, Vol. C47.	
	R197	GIUSEPPE, G. P. <i>et al.</i> "The crystal structure of a sulfamethoxazole-trimethoprim 1:1 molecular compound" <i>Il Farmaco- Ed. Sc.</i> , pp. 138-151, Vol. 35.	
	R198	GOSWAMI, S. <i>et al.</i> "2-aminopyrimidine-fumaric acid cocrystal" <i>Acta Cryst.</i> , 1999, pp. 583-585, Vol. C55.	
	R199	HAYNES, D. "Supramolecular synthon competition in organic sulfonates: A CSD survey" <i>Cryst. Eng. Comm.</i> , 2004, pp. 584-588, Vol. 6, No. 95.	
	R200	GOSWAMI, S. <i>et al.</i> "1:1 Hetero-assembly of 2-amino-pyrimidine and (+)-camphoric acid" <i>Acta Cryst.</i> , 2000, pp. 477-478, Vol. C56.	
	R201	GOSWAMI, S. <i>et al.</i> "Molecular recognition induced supramolecular array of 2-aminopyrimidine with terephthalic acid, 1,4-phenylenediacetic acid and fumaric acid in solid state via H-bonding and $\pi$ -stacking interactions" <i>Supramolecular Chemistry</i> , 1999, pp. 25-33, Vol. 11.	
	R202	GRAJA, A. <i>et al.</i> "Interplay of acceptor molecule shape, crystal structure and physical properties of a new molecular complex $C_{70} \cdot 2[(Ph_3P) AuCl]$ " <i>Chemical Physics Letters</i> , November 19, 1999, pp. 725-732. Vol. 313.	
	R203	HAIXIN, L. <i>et al.</i> "Structure of the 1:1 complex of 6,6'-diquinolyl ether with 5,5-diethylbarbituric acid" <i>Acta Cryst.</i> , 1992, pp. 2096-2098, Vol. C48.	
Examiner Signature	/Jonathan Lau/		Date Considered
			04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

Sheet 28 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R204	HENCK, J. <i>et al.</i> "Disappearing and reappearing polymorphs. The benzocaine:picric acid system" <i>J. Am. Chem. Soc.</i> , 2001, pp. 1834-1841, Vol. 123.	
	R205	HIGUCHI, T. <i>et al.</i> "Complexation of organic substances in aqueous solution by hydroxyaromatic acids and their salts" <i>J. Pharm. Sci.</i> , 1961, pp. 905-909, Vol. 50.	
	R206	HINO, T. <i>et al.</i> "Assessment of nicotinamide polymorphs by differential scanning calorimetry" <i>Thermochimica Acta</i> , 2001, pp. 85-92, Vol. 374.	
	R207	HÖGBERG, T. <i>et al.</i> "Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D <sub>2</sub> antagonist" <i>J. Pharm. Pharmacol.</i> , 1987, pp. 787-796, Vol. 39.	
	R208	HSU, I. <i>et al.</i> "The 2:1 crystal complex of 2-aminopyridine and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 994-997, Vol. B30.	
	R209	HSU, I. <i>et al.</i> "The 1:1 crystal complex of N-methyl-2-pyridone and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 998-1001, Vol. B30.	
	R210	HSU, I. <i>et al.</i> "The crystalline complex (1:1) of salicylamide and 5-ethyl-5-isoamylbarbituric acid (amobarbital)" <i>Acta Cryst.</i> , 1974, pp. 843-846, Vol. B30.	
	R211	HSU, I. <i>et al.</i> "The crystal structure of the 1:1 complex of acetamide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 974-979, Vol. B30.	
	R212	HSU, I. <i>et al.</i> "The crystal structure of the triclinic 1:2 complex of hexamethylphosphoramide with 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 1299-1304, Vol. B30.	
	R213	HSU, I. <i>et al.</i> "Hydrogen bonding NH...N of barbiturates: The 1:1 crystal complex of imidazole and 5,5-diethylbarbituric acid (barbital)" <i>Acta Cryst.</i> , 1974, pp. 988-993, Vol. B30.	
	R214	IBRAGIMOV, B. "A simple correlation between the structures of different crystal modifications of a given host-guest complex and their crystallization temperatures" <i>Journal of Inclusion of Phenomena and Macrocyclic Chemistry</i> , 1999, pp. 345-353, Vol. 34.	
Examiner Signature	/Jonathan Lau/		Date Considered 04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet

29

of

39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R215	ISHIDA, T. <i>et al.</i> "Structural study of histamine H <sub>2</sub> -receptor antagonists. Five 3-[2-(diamino-methyleneamino)-4-thiazolymethylthio] propionamidine and -amide derivatives" <i>Acta Cryst.</i> , 1989, pp. 505-512, Vol. B45.	
	R216	KATAKAI, R. <i>et al.</i> "Stepwise synthesis of oligopeptides with N-carboxy- $\alpha$ -amino acid anhydrides. IV. Glycine NCA" <i>J. Org. Chem.</i> , 1972, pp. 327-329, Vol. 37, No. 2.	
	R217	KAWAKAMI, Y. <i>et al.</i> "The rationale for E2020 as a potent acetylcholinesterase inhibitor" <i>Bioorganic &amp; Medicinal Chemistry</i> , 1996, pp. 1429-1446, Vol. 4, No. 9.	
	R218	KELDERS, H. <i>et al.</i> "Automated protein crystallization and a new crystal form of a subtilisin: eglin complex" <i>Protein Engineering</i> , 1987, pp. 301-303, Vol. 1, No. 4.	
	R219	KHALIL, R. M. "Complexation of paracetamol with xanthine derivatives" <i>Egypt. J. Pharm. Sci.</i> , 1992, pp. 757-769, Vol. 33, No. 5-6.	
	R220	KIM, S. "Crystal structure of the 1:1 complex of 5-fluorouracil and 9-ethylhypoxanthine" <i>Science</i> , November 24, 1967, pp. 1046-1048, Vol. 158, No. 3804.	
	R221	KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-barbital complex" <i>Journal of Pharmaceutical Sciences</i> , May 1971, pp. 699-703, Vol. 60, No. 5.	
	R222	KIRYU, S. <i>et al.</i> "Crystal structure of a 1:1 aminopyrine-cyclobarbitol complex" <i>Chem. Pharm. Bull.</i> , 1974, pp. 1588-1592, Vol. 22.	
	R223	KLEIN, C. <i>et al.</i> "Molecular structure of two conformationally restrained fentanyl analogues: cis- and trans-isomers of N-{3-methyl-1-[1,2,3,4-tetrahydro) naphthyl]-4-piperidinyl}-N-phenylpropanamide" <i>Journal of Pharmaceutical Sciences</i> , November 1985, pp. 1147-1151, Vol. 74, No. 11.	
	R224	KOSHIMA, H. <i>et al.</i> "Photoreactivities of two kinds of bimolecular crystals formed from acridine and phenothiazine" <i>J. Chem. Soc., Perkins Trans. 2</i> , 1997, pp. 2033-2038.	
	R225	KOSHIMA, H. <i>et al.</i> "Polymorphs of a cocrystal with achiral and chiral structures prepared by pseudoseeding: tryptamine/hydrocinnamic acid" <i>Crystal Growth &amp; Design</i> , 2001, pp. 355-357, Vol. 1, No. 5.	
Examiner Signature	/Jonathan Lau/		Date Considered 04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet	30	of	39
-------	----	----	----

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R226	KRISHNAMOHAN SHARMA, C. V. <i>et al.</i> "X-ray crystal structure of C <sub>6</sub> H <sub>3</sub> (CO <sub>2</sub> H) <sub>3</sub> -1,3,5•1.5(4,4'-bipy): a 'super trimesic acid' chicken-wire grid" <i>Chem. Commun.</i> , 1996, pp. 2655-2656.	
	R227	KURODA, R. <i>et al.</i> "Generation of a co-crystal phase with coloristic properties via solid state grinding procedures" <i>Chem. Commun.</i> , 2002, pp. 2848-2849.	
	R228	LEISEROWITZ, L. <i>et al.</i> "The molecular packing modes and hydrogen-bonding properties of amide: dicarboxylic acid complexes" <i>Acta Cryst.</i> , 1977, pp. 2719-2733, Vol. B33.	
	R229	LEISEROWITZ, L. "Molecular packing modes. Carboxylic acids" <i>Acta Cryst.</i> , 1976, pp. 775-802, Vol. B32.	
	R230	LYNCH, D. <i>et al.</i> "Molecular cocrystals of carboxylic acids. XXXI adducts of 2-aminopyrimidine and 3-amino-1,2,4-triazole with heterocyclic carboxylic acids" <i>Aust. J. Chem.</i> , 1998, pp. 403-408, Vol. 51.	
	R231	MACGILLIVRAY, L. <i>et al.</i> "Supramolecular control of reactivity in the solid state using linear molecular templates" <i>J. Am. Chem. Soc.</i> , 2000, pp. 7817-7818, Vol. 122.	
	R232	MATHIAS, J. <i>et al.</i> "Structural preferences of hydrogen-bonded networks in organic solution- the cyclic CA <sub>3</sub> • M <sub>3</sub> 'rosette'" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4316-4325, Vol. 116.	
	R233	MASTROPAOLO, D. <i>et al.</i> "Hydrogen bonding interaction of diphenylhydantoin and 9-ethyladenine" <i>Molecular Pharmacology</i> , 1983, pp. 273-277, Vol. 23.	
	R234	MARYANOFF, B. "Stereochemistry in a medium-sized ring. Highly diastereoselective N-oxidation of a substituted 3-benzazonine. X-ray crystal structure of an unusual complex between an amine N-oxide and saccharin" <i>J. Org. Chem.</i> , 1990, pp. 760-764, Vol. 55.	
	R235	MARTIN, R. <i>et al.</i> "The caffeine-potassium chlorogenate molecular complex" <i>Phytochemistry</i> , 1987, pp. 273-279, Vol. 26, No. 1.	
	R236	ANDERSON, J. "Constitution of aurous compounds: Gold mirrors" <i>Nature</i> , October 2, 1937, pp. 583-584, Letters to the Editor.	
Examiner Signature	/Jonathan Lau/		Date Considered 04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

Sheet 31 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R237	ROBBINS, A. H. <i>et al.</i> "The crystal structure of the 1:2 adduct of potassium triiodide and 5,5-diethylbarbituric acid (barbital)" <i>American Crystallographic Association- Series 2, Papers and Abstracts</i> , 1973, p. 87.	
	R238	BEERGES, P. <i>et al.</i> "Phenothiazine tetracyanoethylene" <i>Private Communication</i> , 1994.	
	R239	MADARASZ, J. <i>et al.</i> "Thermal, ftr and xrd study on some 1:1 molecular compounds of theophylline" <i>Journal of Thermal Analysis and Calorimetry</i> , 2002, pp. 281-290, Vol. 69.	
	R240	CARONNA, T. <i>et al.</i> "Halogen bonding and $\pi\cdots\pi$ stacking control reactivity in the solid state" <i>J. Am. Chem. Soc.</i> , 2004, pp. 4500-4501, Vol. 126.	
	R241	ZERKOWSKI, J. <i>et al.</i> "Steric control of secondary, solid-state architecture in 1:1 complexes of melamines and barbiturates that crystallize as crinkled tapes" <i>J. Am. Chem. Soc.</i> , 1994, pp. 4298-4304, Vol. 116.	
	R242	ZAITU, S. <i>et al.</i> "1:1 Molecular complex of theophylline and <i>p</i> -nitroaniline" <i>Acta Cryst.</i> , 1995, pp. 2390-2392, Vol. C51.	
	R243	KOFLER, L. <i>et al.</i> , <i>Thermal micromethods for the study of organic compounds and their mixtures</i> , pp. 1-145, 148-351, 354-386, Innsbruck, Austria, 1980.	
	R244	QUEHENBERGER, H. "Concerning organic molecular compounds and their polymorphism" <i>Monatshefte für Chemie</i> , 1949, pp. 595-606, Vol. 80, No. 5.	X
	R245	WIEDENFELD, H. <i>et al.</i> "The crystal structure of the theophylline-urea complex" <i>Arch. Pharm.</i> , 1986, pp. 654-659, Vol. 319.	X
	R246	BUNICK, G. <i>et al.</i> "The crystal and molecular structure of the complex 2,6-diamino-9-ethylpurine 5,5-diethylbarbituric acid" <i>American Crystallographic Association, Abstract Papers</i> Winter 1976, p. 30.	
	R247	BUCZAK, G. <i>et al.</i> "Crystal structure and vibrational spectra of the 1:1 and 1:2 complexes of pyridine betaine with pentachlorophenol" <i>Journal of Molecular Structure</i> , 1997, pp. 143-151, Vol. 436-437.	
Examiner Signature	/Jonathan Lau/		Date Considered 04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

Sheet 32 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R248	TOMURA, M. <i>et al.</i> "One-dimensional zigzag chain structures with intermolecular C-H... $\pi$ and C-H...O interactions consisted of phthalic acid and pyridine derivatives" <i>Chemistry Letters</i> , 2001, pp. 532-533.	
	R249	ZERKOWSKI, J. <i>et al.</i> "Design of organic structures in the solid state: molecular tapes based on the network of hydrogen bonds present in the cyanuric acid-melamine complex" <i>J. Am. Chem. Soc.</i> , 1994, pp. 2382-2391, Vol. 116.	
	R250	HARKEMA, S. <i>et al.</i> "The crystal structure of urea oxalic acid (2:1)" <i>Acta Cryst.</i> , 1972, pp. 1646-1648, Vol. B28.	
	R251	KRANTZ, J. <i>et al.</i> "Sodium theophylline glycinate" <i>Journal of the American Pharmaceutical Association</i> , 1946, pp. 248-250.	
	R252	DATTA, S. <i>et al.</i> "Crystal structures of drugs: advances in determination, prediction and engineering" <i>Nature</i> , January 2004, pp. 42-57, Vol. 3.	
	R253	AAKERÖY, C. <i>et al.</i> "Charge-assisted hydrogen bonds and halogen-halogen interactions in organic salts: benzylammonium benzoates and pentafluorobenzoates" <i>Structural Chemistry</i> , 1999, pp. 229-242, Vol. 10, No. 3.	
	R254	CHILDS, S. <i>et al.</i> "Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids" <i>J. Am. Chem. Soc.</i> , 2004, pp. 13335-13342, Vol. 126.	
	R255	AAKERÖY, C. <i>et al.</i> "Modular supramolecular synthesis based on a dominance hierarchy of intermolecular interactions (Abstract)" 223 <sup>rd</sup> ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.	
	R256	HELFRICH, B. <i>et al.</i> "Polymorphism as an indication of structural versatility (Abstract)" 223 <sup>rd</sup> ACS National Meeting in Orlando, FL., April 7-11, 2002, published by the American Chemical Society, Washington, D.C.	
	R257	WEBER, E. <i>et al.</i> "Synthesis of new Schiff bases: reaction of monofluorobenzaldehydes with 3-aminosulfolane hydrochloride (Abstract)" 216 <sup>th</sup> ACS National Meeting in Boston, MA., August 23-27, 1998, published by the American Chemical Society, Washington, D.C.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet

33

of

39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R258	SCARBROUGH, F. <i>et al.</i> "Crystal structure of a complex between lumiflavin and 2,6-diamino-9-ethylpurine: a flavin adenine dinucleotide model exhibiting charge-transfer interactions" <i>Proc. Natl. Acad. Sci. USA</i> , November 1976, pp. 3807-3811, Vol. 73, No. 11.	
	R259	MUNN, R. <i>et al.</i> "A Model for resonance-assisted hydrogen bonding in crystals and its graph set analysis" <i>J. Phys. Chem. A</i> , 2001, pp. 6938-6942, Vol. 105.	
	R260	LYNCH, D. <i>et al.</i> "1:1 Molecular complexes of 4-amino-N-(4,6-dimethylpyrimidin-2-yl) benzene-sulfonamide (sulfamethazine) with indole-2-carboxylic acid and 2,4-dinitrobenzoic acid" <i>Aust. J. Chem.</i> , 2000, pp. 383-387, Vol. 53.	
	R261	AAKERÖY, C. <i>et al.</i> "Solid state, crystal engineering and hydrogen bonds" <i>Comprehensive Coordination Chemistry II</i> (ed. by McCleverty, J. <i>et al.</i> ), pp. 679-688, Elsevier Ltd., Oxford, UK.	
	R262	LEVIN, B. <i>et al.</i> "The not-so-trivial synthesis and characterization of heterocyclic boronic acids (Abstract)" 38 <sup>th</sup> Midwest Regional Meeting of the American Chemical Society in Columbia, MO., November 5-7, 2003, published by the American Chemical Society, Washington, D.C.	
	R263	SMITH, G. <i>et al.</i> "Interactions of aromatic carboxylic acids with quinolin-8-ol (oxine): Synthesis and the crystal structures of the proton-transfer compounds with the nitro-substituted benzoic acids" <i>Aust. J. Chem.</i> , 2001, pp. 171-175, Vol. 54.	
	R264	STALKER, R. <i>et al.</i> "Asymmetric synthesis of two new conformationally constrained lysine derivatives" <i>Tetrahedron</i> , 2002, pp. 4837-4849, Vol. 58.	
	R265	VOET, D. <i>et al.</i> "Barbiturates and adenine derivatives. Molecular structure of a hydrogen-bonded complex" <i>Journal of the American Chemical Society</i> , August 9, 1972, pp. 5888-5891, Vol. 94, No. 16.	
	R266	LE JEUNNE, C. <i>et al.</i> "Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks" <i>Eur. Neurol.</i> , 1999, pp. 37-43, Vol. 41.	
	R267	AAKERÖY, C. <i>et al.</i> "Hydrogen-bonded layers of hydrogentartrate anions: two-dimensional building blocks for crystal engineering" <i>J. Mater. Chem.</i> , 1993, pp. 1129-1135, Vol. 3, No. 11.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

Sheet 34 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R268	HU, Z. <i>et al.</i> "Separation of 4-aminobenzoic acid by cocrystallization: Crystal structure of the complex of 4-aminobenzoic acid with (2R,3R)-tartaric acid" <i>Journal of Chemical Crystallography</i> , December 2002, pp. 525-529, Vol. 32, No. 12.	
	R269	GUARRERA, D. <i>et al.</i> "Molecular self-assembly in the solid state. The combined use of solid state NMR and differential scanning calorimetry for the determination of phase constitution" <i>Chem. Mater.</i> , 1994, pp. 1293-1296, Vol. 6.	
	R270	DOI, M. <i>et al.</i> "Conformational study of a potent human renin inhibitor: x-ray crystal structure of isopropyl (2R, 3S) -4-cyclohexyl-2-hydroxy-3-{N-[(2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl) propionyl] -L-histidylamino}butyrate (KRI-1314), a pentapeptide analogue with amino acid sequence corresponding to the cleavage site of angiotensinogen" <i>J. Chem. Soc. Perkin Trans. 1</i> , 1991, pp. 1153-1158.	
	R271	CRIHFELD, A. <i>et al.</i> "Crystal engineering through halogen bonding. 2. Complexes of diacetylene-linked heterocycles with organic iodides" <i>Crystal Growth &amp; Design</i> , 2003, pp. 313-320, Vol. 3, No. 3.	
	R272	AAKERÖY, C. <i>et al.</i> "A versatile route to porous solids: organic-inorganic hybrid materials assembled through hydrogen bonds" <i>Angew. Chem. Int. Ed.</i> , 1999, pp. 1815-1819, Vol. 38, No. 12.	
	R273	SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-theophylline complex.	
	R274	SHEFTER, E. <i>et al.</i> , ACS, Abstr. Papers (Summer), 1970, 35, compound name: sulfathiazole-sulfanilamide complex.	
	R275	WIEDENFELD, H. <i>et al.</i> "Solubilization of aminophenazone" <i>Arch. Pharm.</i> , 1982, pp. 633-641, Vol. 315.	x
	R276	CACCIAPUOTI, A. <i>et al.</i> "In vitro and in vivo activities of SCH 56592 (Posaconazole), a new triazole antifungal agent, against <i>Aspergillus</i> and <i>Candida</i> " <i>Antimicrobial Agents and Chemotherapy</i> , August 2000, pp. 2017-2022, Vol. 44, No. 8.	
	R277	CALLAHAN, J.C. <i>et al.</i> "Equilibrium moisture content of pharmaceutical excipients" <i>Drug Development and Industrial Pharmacy</i> , 1982, pp. 355-369, Vol. 8, No. 3.	
	R278	DANNAOUI, E. <i>et al.</i> "Acquired itraconazole resistance in <i>Aspergillus fumigatus</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 2001, pp. 333-340, Vol. 47.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

35

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R279	DENNING, D. W. <i>et al.</i> "In vitro activity of Saperconazole (R66 905) compared with Amphotericin B and Itraconazole against <i>Aspergillus</i> species" <i>Eur. J. Clin. Microbial. Infect. Dis.</i> , 1990, pp. 693-697, Vol. 9.	
	R280	DRESSMAN, J. B. <i>et al.</i> "Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms" <i>Pharmaceutical Research</i> , 1998, pp. 11-22, Vol. 15, No. 1.	
	R281	EBERT, W. R. "Soft elastic gelatin capsules: a unique dosage form" <i>Pharmaceutical Technology</i> , October 1977, pp. 44-50, Vol. 1, No. 5.	
	R282	GASCON, M.-P. <i>et al.</i> "In vitro forecasting of drugs which may interfere with the biotransformation of midazolam" <i>Eur. J. Clin. Pharmacol.</i> , 1991, pp. 573-578, Vol. 41.	
	R283	HEERES, J. <i>et al.</i> "Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones" <i>J. Med. Chem.</i> , 1984, pp. 894-900, Vol. 27.	
	R284	HONIG, P. K. <i>et al.</i> "Itraconazole affects single-dose Terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics" <i>J. Clin. Pharmacol.</i> , 1993, pp. 1201-1206, Vol. 33.	
	R285	IMAI, T. <i>et al.</i> "Successful treatment of cerebral Aspergillosis with a high oral dose of Itraconazole after excisional surgery" <i>Internal Medicine</i> , October 1999, pp. 829-832, Vol. 38, No. 10.	
	R286	KOVACS, J. <i>et al.</i> "New type of bridged monoamino- $\beta$ -cyclodextrins" <i>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</i> , 1996, pp. 53-56, Vol. 25.	
	R287	LAVRIJSEN, A. P. M. <i>et al.</i> "Hepatic injury associated with itraconazole" <i>The Lancet</i> , July 25, 1992, pp. 251-252, Vol. 340.	
	R288	NEUVONEN, P. J. <i>et al.</i> "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid" <i>Clinical Pharmacology &amp; Therapeutics</i> , 1996, pp. 54-61, Vol. 60, No. 1.	
	R289	NOMEIR, A. A. <i>et al.</i> "Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys" <i>Antimicrobial Agents and Chemotherapy</i> , March 2000, pp. 727-731, Vol. 44, No. 3.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

36

of

39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R290	ODDS, F. C. "Antifungal activity of saperconazole (R 66 905) <i>in vitro</i> " <i>Journal of Antimicrobial Chemotherapy</i> , 1989, pp. 533-537, Vol. 24.	
	R291	SAKSENA, A. K. <i>et al.</i> "Advances in the chemistry of novel broad-spectrum orally active azole antifungals: recent studies leading to the discovery of SCH 56592" in <i>Advances in the Chemistry of Novel Broad-Spectrum Orally Active Azole Antifungals</i> (Royal Soc. Chem., Cambridge), 1997, pp. 180-199.	
	R292	SAKSENA, A. K. <i>et al.</i> "Concise asymmetric routes to 2,2,4-trisubstituted tetrahydrofurans via chiral titanium imide enolates: key intermediates towards synthesis of highly active azole antifungals SCH 51048 and SCH 56592" <i>Tetrahedron Letters</i> , 1996, pp. 5657-5660, Vol. 37, No. 32.	
	R293	HEPPERLE, M. <i>et al.</i> "Mono <i>N</i> -arylation of piperazine(III): metal-catalyzed <i>N</i> -arylation and its application to the novel preparations of the antifungal posaconazole and its advanced intermediate" <i>Tetrahedron Letters</i> , 2002, pp. 3359-3363, Vol. 43.	
	R294	VAN CUTSEM, J. V. <i>et al.</i> "Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals" <i>Antimicrobial Agents and Chemotherapy</i> , December 1989, pp. 2063-2068, Vol. 33, No. 12.	
	R295	WEST, A. R., "Solid Solutions" In: <i>Solid State Chemistry and its Applications</i> , 1988, pp. 358-365, Wiley, NY.	
	R296	ARONHIME, J. <i>et al.</i> "Crystalline forms of pharmaceuticals and characterization thereof", Oral Presentation, March 8, 2005, USPTO, Alexandria, VA.	
	R297	DESIRAJU, G. R. "Chemistry beyond the molecule" <i>Nature</i> , July 26, 2001, pp. 397-400, Vol. 412.	

Examiner  
Signature

/Jonathan Lau/

Date

Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 37 of 39

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI 2900C3XC2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R298	Physician's Desk Reference, 56 <sup>th</sup> Ed., pp. 1800-1804, 2002.	
	R299	KIM, H. <i>et al.</i> "High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum" <i>Journal of Chromatography B</i> , 2000, pp. 93-98, Vol. 738.	
	R300	VIPPAGUNTA, S. R. <i>et al.</i> "Crystalline solids" <i>Advanced Drug Delivery Reviews</i> , 2001, pp. 3-26, Vol. 48.	
	R301	MCCRONE, W. C. "Polymorphism", In: <i>The Physics and Chemistry of the Organic Solid State</i> , Vol. II, FOX, D. <i>et al.</i> (eds.), 1965, pp. 725-767, Interscience, New York.	
	R302	LEGER, J.M. <i>et al.</i> "Crystal Structure of the 1:1 Sulfacetamide-Caffeine Complex" <i>Acta Cryst.</i> , 1977, pp. 1455-1459, Vol. B33.	x
	R303	SIMONOV, Y. <i>et al.</i> "Structure of the caffeine-copper(II) acetate additional compound", <i>Izvestiya Akademii Nauk Moldavskoi SSR, Seriya Fiziko-Tekhnicheskikh i Matematicheskikh Nauk</i> , 1972, Vol. 3, pp. 83-84, abstract only.	
	R304	WEISSBUCH, I. <i>et al.</i> "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries" <i>Acta Cryst.</i> , 1995, B51:115-148.	
	R305	FAUGHT, E. <i>et al.</i> "Topiramate Dose-Ranging Trial in Refractory Partial Epilepsy", <i>Amer. Epilepsy Soc. Proc.</i> , (1995), pg. 33, Vol. 36, Supp. 4.	
	R306	PRIVITERA, M. <i>et al.</i> "Dose-Ranging Trial with Higher Doses of Topiramate in Patients with Resistant Partial Seizures", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.	
	R307	SACHDEO, S. K. <i>et al.</i> "Topiramate: Double-Blind Trial as Monotherapy", <i>Amer. Epilepsy Soc. Proc.</i> , 1995, pg. 33, Vol. 36, Supp. 4.	
	R308	Press Release. "Clinical Development of Topiramate for Obesity Extended to Simplify Dosing, Improve Tolerability". <a href="http://www.orthomcneil.com/news/article020402.html">http://www.orthomcneil.com/news/article020402.html</a> (February 4, 2002), N.J.	x

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet 38 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R309	ROSENFELD, W. E. "Topiramate: A Review of Preclinical, Pharmacokinetic, and Clinical Data", <i>Clinical Therapeutics</i> , 1997, pp. 1294-1308, Vol. 19, No. 6.	
	R310	Physician's Desk Reference, 56 <sup>th</sup> Edition, 2002, pp. 2590-2595.	
	R311	DATABASE WPI, Section Ch, Week 197936, Derwent Publishing Ltd., London, Great Britain, Class B02, AN 1979-65538B, XP002282989 and JP 54 095589A (Sumitomo) 1979 Abstract.	
	R312	FITZGERALD, G. A. "The Coxibs, Selective Inhibitors of Cyclooxygenase-2", <i>New England Journal of Medicine</i> , Vol. 345, No. 6, August 9, 2001, pp. 433-442.	
	R313	AAKERÖY, C. <i>et al.</i> "Low-dimensional architectures of silver coordination compounds assembled via amide-amide hydrogen bonds" <i>Crystal Engineering</i> , 1998, pp. 39-49, Vol. 1, No. 1.	
	R314	AAKERÖY, C. <i>et al.</i> "Molecular mechanics and crystal engineering" <i>Crystal Engineering</i> (ed. by Seddon, K. R. <i>et al.</i> ), 1999, pp. 69-82, Kluwer Academic Publishers, The Netherlands.	
	R315	AAKERÖY, C. <i>et al.</i> "New building blocks for crystal engineering. Syntheses and crystal structures of oxime-substituted pyridines" <i>Cryst. Eng. Comm.</i> , 2000, pp. 1-6, Vol. 27.	
	R316	AAKERÖY, C. <i>et al.</i> "Novel colorless composite materials for nonlinear optics" <i>Adv. Mater.</i> , 1993, pp. 364-367, Vol. 5, No. 5.	
	R317	AAKERÖY, C. <i>et al.</i> "Organic assemblies of 2-pyridones with dicarboxylic acids" <i>Tetrahedron</i> , 2000, pp. 6693-6699, Vol. 56.	
	R318	AAKERÖY, C. <i>et al.</i> "Pitfalls in the supramolecular assembly of silver(I) coordination compounds" <i>Journal of Molecular Structure</i> , 1999, pp. 91-101, Vol. 474.	
	R319	AAKERÖY, C. <i>et al.</i> "A structural study of 2-amino-5-nitropyridine and 2-amino-3-nitropyridine: intermolecular forces and polymorphism" <i>J. Mater. Chem.</i> , 1998, pp. 1385-1389, Vol. 8, No. 6.	
	R320	AAKERÖY, C. <i>et al.</i> "Supramolecular assembly of low-dimensional silver (I) architectures via amide-amide hydrogen bonds" <i>Chem. Commun.</i> , 1998, pp. 1067-1068.	
	R321	AAKERÖY, C. <i>et al.</i> "'Total synthesis' supramolecular style: design and hydrogen-bond-directed assembly of ternary supermolecules" <i>Angew. Chem. Int. Ed.</i> , 2001, pp. 3240-3242, Vol. 40, No. 17.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/747,742
Filing Date	December 29, 2003
First Named Inventor	Mark Tawa
Group Art Unit	1623
Examiner Name	Jonathan S. Lau
Attorney Docket Number	TPI.2900C3XC2

Sheet 39 of 39

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R322	AAKERÖY, C. <i>et al.</i> "Two-fold interpenetration of 3-D nets assembled via three-co-ordinate silver(I) ions and amide-amide hydrogen bonds" <i>J. Chem. Soc., Dalton Trans.</i> , 1998, pp. 1943-1945.	
	R323	AHN, S. <i>et al.</i> "Polymorphs of a 1:1 cocrystal with tunnel and layer structures: <i>p,p'</i> -biphenol/dimethyl sulfoxide" <i>Crystal Growth &amp; Design</i> , 2001, pp. 107-111, Vol. 1, No. 2.	
	R324	AAKERÖY, C. <i>et al.</i> "Hydrogen-bonding in solids" <i>Crystal Engineering</i> (ed. by Seddon, K. R. <i>et al.</i> ), 1999, pp. 303-324, Kluwer Academic Publishers, The Netherlands.	
	R325	AAKERÖY, C. <i>et al.</i> "Di-hydroxy malonic acid as a building block of hydrogen-bonded 3-dimensional architectures" <i>Journal of Chemical Crystallography</i> , 1998, pp. 111-117, Vol. 28, No. 2.	
	R326	AAKERÖY, C. <i>et al.</i> "Do polymorphic compounds make good cocrystallizing agents? A structural case study that demonstrates the importance of synthon flexibility" <i>Crystal Growth &amp; Design</i> , 2003, pp. 159-165, Vol. 3, No. 2.	
	R327	AAKERÖY, C. <i>et al.</i> "Heteromeric intermolecular interactions as synthetic tools for the formation of binary co-crystals" <i>Cryst. Eng. Comm.</i> , 2004, pp. 19-24, Vol. 6, No. 5.	
	R328	AAKERÖY, C. <i>et al.</i> "Hydrogen-bond assisted assembly of organic and organic-inorganic solids" <i>Crystal Engineering: From Molecules and Crystals to Materials</i> , 1999, pp. 89-106, Kluwer Academic Publishers, The Netherlands.	
	R329	AAKERÖY, C. <i>et al.</i> "A high-yielding supramolecular reaction" <i>J. Am. Chem. Soc.</i> , 2002, 14425-14432, Vol. 124.	
	R330	AAKERÖY, C. <i>et al.</i> "The hydrogen bond and crystal engineering" <i>Chemical Society Reviews</i> , 1993, pp. 397-407.	
	R331	AMMAR, H. O. <i>et al.</i> "Effect of Aromatic Hydrotropes on the Solubility of Carbamazepine. Part II: Effect of Nicotinamide, Sodium Salts of Benzoic, Naphthoic and Nicotinic Acids" <i>Egypt. J. Pharm. Sci.</i> , 1994, pp. 209-223, Vol. 35, No. 1-6.	
	R332	DE JONG, E. M. G. J. <i>et al.</i> "Dystrophic Psoriatic Fingernails Treated with 1% 5-Fluorouracil in a Nail Penetration-Enhancing Vehicle: A Double-Blind Study" <i>Dermatology</i> , 1999, pp. 313-318, Vol. 199, No. 4.	
	R333	DVORKIN <i>et al.</i> "Crystal and Molecular Structure of a Complex 18-crown-6 with 6-chloro-7-sulfamido-3,4-dihydro-1,2,4-benzothiadiazine-1, 1-dioxide (hypothiazide) of 1:1 Composition" <i>Kristallagرافيya</i> , 1990, pp. 682-686, Vol. 35, No. 3 (with English abstract).	
	R334	WALSH, R. D. <i>et al.</i> "Crystal Engineering of the Composition of Pharmaceutical Phases" <i>Chem. Commun.</i> , 2003, pp. 186-187.	

Examiner  
Signature

/Jonathan Lau/

Date  
Considered

04/13/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.